107 related articles for article (PubMed ID: 8460096)
21. Inhibition of the growth of transplanted rat pancreatic acinar carcinoma with octreotide.
Hajri A; Bruns C; Marbach P; Aprahamian M; Longnecker DS; Damgé C
Eur J Cancer; 1991; 27(10):1247-52. PubMed ID: 1683556
[TBL] [Abstract][Full Text] [Related]
22. Effect of a new CCK-receptor antagonist, CR 1409, on pancreatic growth induced by caerulein, CCK-8, bombesin and gastrin-releasing peptide in the rat.
Hajri A; Aprahamian M; Damgé C
Digestion; 1989; 43(1-2):66-72. PubMed ID: 2806757
[TBL] [Abstract][Full Text] [Related]
23. Effects of cholecystokinin and bombesin on development of azaserine-induced pancreatic tumours in rats: modulation by the cholecystokinin receptor antagonist lorglumide.
Meijers M; Appel MJ; van Garderen-Hoetmer A; Lamers CB; Rovati LC; Jansen JB; Woutersen RA
Carcinogenesis; 1992 Sep; 13(9):1525-8. PubMed ID: 1394835
[TBL] [Abstract][Full Text] [Related]
24. Characterization of a new CCK antagonist, L364,718: in vitro and in vivo studies.
Louie DS; Liang JP; Owyang C
Am J Physiol; 1988 Sep; 255(3 Pt 1):G261-6. PubMed ID: 2458681
[TBL] [Abstract][Full Text] [Related]
25. Lorglumide and loxiglumide inhibit gastrin-stimulated DNA synthesis in a rat tumoral acinar pancreatic cell line (AR42J).
Seva C; Scemama JL; Bastié MJ; Pradayrol L; Vaysse N
Cancer Res; 1990 Sep; 50(18):5829-33. PubMed ID: 2393852
[TBL] [Abstract][Full Text] [Related]
26. Stimulation of pancreatic growth by cholecystokinin is mediated by high affinity receptors on rat pancreatic acinar cells.
Dawra R; Saluja A; Lerch MM; Saluja M; Logsdon C; Steer M
Biochem Biophys Res Commun; 1993 Jun; 193(3):814-20. PubMed ID: 8323557
[TBL] [Abstract][Full Text] [Related]
27. Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990.
Smith JP; Solomon TE; Bagheri S; Kramer S
Dig Dis Sci; 1990 Nov; 35(11):1377-84. PubMed ID: 2226098
[TBL] [Abstract][Full Text] [Related]
28. Stimulation of in vivo pancreatic growth in the rat is mediated specifically by way of cholecystokinin-A receptors.
Povoski SP; Zhou W; Longnecker DS; Jensen RT; Mantey SA; Bell RH
Gastroenterology; 1994 Oct; 107(4):1135-46. PubMed ID: 7523219
[TBL] [Abstract][Full Text] [Related]
29. Proglumide analogues CR 1409 and CR 1392 inhibit cholecystokinin-stimulated insulin release more potently than exocrine secretion from the isolated perfused rat pancreas.
Okabayashi Y; Otsuki M; Nakamura T; Fujii M; Tani S; Fujisawa T; Koide M; Hasegawa H; Baba S
Pancreas; 1990 May; 5(3):291-7. PubMed ID: 2188254
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of cholecystokinin receptors in azaserine-induced neoplasms of the rat pancreas.
Bell RH; Kuhlmann ET; Jensen RT; Longnecker DS
Cancer Res; 1992 Jun; 52(12):3295-9. PubMed ID: 1596887
[TBL] [Abstract][Full Text] [Related]
31. Effects of the cholecystokinin A receptor antagonist loxiglumide on the proliferation and cell cycle time of pancreatic acinar cells in rats.
Kanemitsu D; Sakagami J; Motoyoshi T; Nakajima T; Kataoka K
Pancreas; 2006 Mar; 32(2):190-6. PubMed ID: 16552340
[TBL] [Abstract][Full Text] [Related]
32. Cholecystokinin receptor characterization and cholecystokinin-A receptor messenger RNA expression in transgenic mouse pancreatic carcinomas and dysplastic pancreas.
Povoski SP; Zhou W; Longnecker DS; Bell RH
Oncol Res; 1994; 6(9):411-7. PubMed ID: 7703527
[TBL] [Abstract][Full Text] [Related]
33. Characterization of a new cholecystokinin receptor antagonist FK480 in in vitro isolated rat pancreatic acini.
Akiyama T; Otsuki M
Pancreas; 1994 May; 9(3):324-31. PubMed ID: 8022754
[TBL] [Abstract][Full Text] [Related]
34. Severe subcellular damage in the rat exocrine pancreas after pancreatobiliary diversion.
Sarraf CE; Watanapa P; Emons VE; Williamson RC; Alison MR
Pancreas; 1993 May; 8(3):338-45. PubMed ID: 8483876
[TBL] [Abstract][Full Text] [Related]
35. CCK antagonists reveal that CCK-8 and JMV-180 interact with different sites on the rat pancreatic acinar cell CCKA receptor.
Yule DI; Williams JA
Peptides; 1994; 15(6):1045-51. PubMed ID: 7527529
[TBL] [Abstract][Full Text] [Related]
36. The effect of long-term administration of lorglumide (CR 1409) on rat pancreatic growth and enzyme composition.
Takács T; Nagy I; Pap A; Varró V
Pancreas; 1990 Sep; 5(5):606-10. PubMed ID: 1700417
[TBL] [Abstract][Full Text] [Related]
37. Loxiglumide (CR1505), a cholecystokinin antagonist, specifically inhibits the growth of human pancreatic cancer lines xenografted into nude mice.
Nio Y; Tsubono M; Morimoto H; Kawabata K; Masai Y; Hayashi H; Manabe T; Imamura M; Fukumoto M
Cancer; 1993 Dec; 72(12):3599-606. PubMed ID: 8252474
[TBL] [Abstract][Full Text] [Related]
38. Effects of the CCK receptor antagonist L364,718 on pancreatic growth in adult and developing animals.
Zucker KA; Adrian TE; Bilchik AJ; Modlin IM
Am J Physiol; 1989 Oct; 257(4 Pt 1):G511-6. PubMed ID: 2478030
[TBL] [Abstract][Full Text] [Related]
39. Proglumide (gastrin and cholecystokinin receptor antagonist) inhibits insulin secretion in vitro.
Verspohl EJ; Wunderle G; Ammon HP; Williams JA; Goldfine ID
Naunyn Schmiedebergs Arch Pharmacol; 1986 Mar; 332(3):284-7. PubMed ID: 3012373
[TBL] [Abstract][Full Text] [Related]
40. CCK receptor antagonist loxiglumide alters uptake of CCK in perfused liver and pancreatic acini of the rat.
Beckh K; Göke R; Ruff W; Koop I; Arnold R; Adler G
Digestion; 1991; 48(2):98-103. PubMed ID: 1868975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
